One of the stigmas holding back the acceptance of medical canna, especially within the medical community, is the lack of information in a format they are trained to receive, analyze and utilize it in. On this episode of Let’s Be Blunt, Montel talks with the CEO Cannaformatics, Dr Itzhak Kurek, about how they are working to change that paradigm. Dr Kurek has published 20 peer reviewed scientific papers and holds 13 granted US and international patents cited over 2,000 times. He received his Ph.D. in Plant Sciences from Tel Aviv University and completed his postdoctoral research at the University of California, Davis, and has conducted research at the Technical University of Munich, John Innes Center Norwich, C.N.R.S Bordeaux and the Lawrence Berkeley National Laboratories. Dr Kurek discusses how Cannaformatics is identifying canna biomarkers, and how that information will benefit patients and medical practicioners in the near future.